Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1982 1
1988 1
1993 1
1994 2
1995 3
1997 2
1998 1
2000 1
2001 1
2003 2
2004 1
2005 2
2006 1
2007 2
2008 3
2009 6
2010 6
2011 1
2012 3
2013 6
2014 5
2015 2
2016 2
2017 3
2018 7
2019 4
2021 2
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
Colombo N, Gadducci A, Sehouli J, Rulli E, Mäenpää J, Sessa C, Montes A, Ottevanger NB, Berger R, Vergote I, D'Incalci M, Churruca Galaz C, Chekerov R, Nyvang GB, Riniker S, Herbertson R, Fossati R, Barretina-Ginesta MP, Deryal M, Mirza MR, Biagioli E, Iglesias M, Funari G, Romeo M, Tasca G, Pardo B, Tognon G, Rubio-Pérez MJ, DeCensi A, De Giorgi U, Zola P, Benedetti Panici P, Aglietta M, Arcangeli V, Zamagni C, Bologna A, Westermann A, Heinzelmann-Schwarz V, Tsibulak I, Wimberger P, Poveda A; INOVATYON study group. Colombo N, et al. Br J Cancer. 2023 Apr;128(8):1503-1513. doi: 10.1038/s41416-022-02108-7. Epub 2023 Feb 9. Br J Cancer. 2023. PMID: 36759720 Free PMC article. Clinical Trial.
The other COVID-19 survivors: Timing, duration, and health impact of post-acute sequelae of SARS-CoV-2 infection.
Lambert N; Survivor Corps; El-Azab SA, Ramrakhiani NS, Barisano A, Yu L, Taylor K, Esperança Á, Mendiola C, Downs CA, Abrahim HL, Hughes T, Rahmani AM, Borelli JL, Chakraborty R, Pinto MD. Lambert N, et al. Among authors: mendiola c. J Clin Nurs. 2024 Jan;33(1):76-88. doi: 10.1111/jocn.16541. Epub 2022 Sep 30. J Clin Nurs. 2024. PMID: 36181315 Free PMC article.
A distinct symptom pattern emerges for COVID-19 long-haul: a nationwide study.
Pinto MD, Downs CA, Huang Y, El-Azab SA, Ramrakhiani NS, Barisano A, Yu L, Taylor K, Esperanca A, Abrahim HL, Hughes T, Herrera MG, Rahamani AM, Dutt N, Chakraborty R, Mendiola C, Lambert N. Pinto MD, et al. Among authors: mendiola c. Sci Rep. 2022 Sep 23;12(1):15905. doi: 10.1038/s41598-022-20214-7. Sci Rep. 2022. PMID: 36151129 Free PMC article.
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y, de Juan Ferré A, Mendiola C, Barretina-Ginesta MP, Gaba Garcia L, Santaballa Bertrán A, Bover Barcelo I, Gil-Martin M, Manzano A, Rubio Pérez MJ, Romeo Marin M, Arqueros Núñez C, García-Martínez E, Gonzalez Martin A. Garcia Garcia Y, et al. Among authors: mendiola c. Int J Gynecol Cancer. 2019 Jul;29(6):1050-1056. doi: 10.1136/ijgc-2019-000256. Int J Gynecol Cancer. 2019. PMID: 31263024 Clinical Trial.
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancer.
Rojas L K, Trilla-Fuertes L, Gámez-Pozo A, Chiva C, Sepúlveda J, Manso L, Prado-Vázquez G, Zapater-Moros A, López-Vacas R, Ferrer-Gómez M, Mendiola C, Espinosa E, Sabidó E, Ciruelos E, Vara JÁF. Rojas L K, et al. Among authors: mendiola c. Ecancermedicalscience. 2019 Jan 15;13:891. doi: 10.3332/ecancer.2019.891. eCollection 2019. Ecancermedicalscience. 2019. PMID: 30792808 Free PMC article.
71 results